CURX Curanex Pharmaceuticals Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 2025942 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-850.0%
TTM EPS YoY-509.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-146.5%
ROA-140.3%
ROIC (approx.)-207.7%
Asset turnover—
Leverage & solvency
Liabilities / assets17.8%
Debt / equity0.00x
Current ratio17.84x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.34x
Accruals ratio-91.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $2.99M | — |
| SG&A expense | $1.25M | $290,386 |
| Operating income | -$4.24M | -$365,062 |
| Interest expense | $8,537 | — |
| Net income | -$4.23M | -$361,506 |
| EPS (basic) | -0.17 | -0.03 |
| EPS (diluted) | -0.17 | -0.03 |
| Weighted avg. shares (diluted) | 25.50M | 13.26M |
| Balance sheet | ||
| Cash & equivalents | $4.97M | $148,891 |
| Current assets | $11.23M | $517,935 |
| Total assets | $11.58M | $517,935 |
| Current liabilities | $137,030 | $14,575 |
| Total liabilities | $361,040 | $14,575 |
| Shareholders' equity | $11.22M | $503,360 |
| Shares outstanding | 1.42M | 1.20M |
| Cash flow statement | ||
| Operating cash flow | -$10.48M | -$555,575 |
| Financing cash flow | $15.31M | $630,100 |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.